QSAM Biosciences (QSAM Biosciences) Risk Assessment

View and export this data going back to 2011. Start your Free Trial

What is QSAM Biosciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of QSAM Biosciences is: No Data: Cannot be evaluated.

Competitive Comparison of QSAM Biosciences's Risk Assessment

For the Biotechnology subindustry, QSAM Biosciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

QSAM Biosciences's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, QSAM Biosciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where QSAM Biosciences's Risk Assessment falls into.

QSAM Biosciences (OTCPK:QSAM) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

QSAM Biosciences Risk Assessment Related Terms

Thank you for viewing the detailed overview of QSAM Biosciences's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

QSAM Biosciences (QSAM Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » QSAM Biosciences Inc (OTCPK:QSAM) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

9442 Capital of Texas Highway North, Plaza 1, Suite 500, Austin, TX, USA, 78759

Website

https://www.qsambio.com

QSAM Biosciences Inc is a clinical-stage novel radiopharmaceutical company. The company is developing treatments for bone cancer and related diseases.

Executives

Adam King	officer: Chief Financial Officer	9442 CAPITAL OF TEXAS HWY N, PLAZA 1, SUITE 500, AUSTIN TX 78759
Link Jr. Charles J	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Adriann Sax	director	7 DORSET COURT,, EAST BRUNSWICK, NJ 08816
David Charles Link	director	2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Douglas R Baum	director, officer: CEO & Director	5000 RAFFEE COVE, AUSTIN TX 78731-1132
C Richard Piazza	director, officer: Executive Chairman	2236 EAST MALL, SUITE 208, UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER A1 V6T 1Z3
Checkmate Strategic Capital Holdings, Llc	other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Strategic Capital 2, Llc	10 percent owner, other: See Explanation of Responses	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Capital Group, Llc	10 percent owner, other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Charles Thomas Paschall	other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Christopher M. Nelson	director, officer: General Counsel	420 ROYAL PALM WAY, SUITE #100, PALM BEACH FL 33480
Scott W. Whitney	director, other: Former Director	96 WINDSOR DRIVE, PINE BROOK NJ 07058
Kevin Bolin	director, officer: Former Chairman & CEO	1081 ROSEDALE DRIVE, ATLANTA GA 30306
Tristan Peitz	director, other: Former Director	C/O Q2POWER TECHNOLOGIES, INC., 420 ROYAL PALM WAY, #100, PALM BEACH FL 33480
Joel David Mayersohn	director	350 EAST LAS OLAS BLVD. #1150, FORT LAUDERDALE FL 33301